701-1115

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2012-11-30

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Moderate APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 51.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-02 (study day 3.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-02 (study day 3.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-26 (study day 27.0); relationship: POSSIBLE

mild assessed

Mild APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2012-12-26 (study day 27.0); relationship: POSSIBLE

moderate assessed

Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 51.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-02 (study day 3.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-02 (study day 3.0); relationship: PROBABLE

moderate assessed

Moderate FATIGUE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-14 (study day 46.0); relationship: REMOTE

Data queries

No data queries.